Table 1. Studies Identified for Analysis.
| Affymetrix Dataset | |||||||
|---|---|---|---|---|---|---|---|
| Dataset (NCBI GEO) | Date of GEO | Cases in dataset | Evaluable | Chemotherapy | Response Definition | Platform | Reference (PMID) |
| GSE4779 | 12/19/08 | 102 | 0 | FEC | Breast only | Affymetrix Human X3P Array | 19122658 |
| GSE18728 | 10/30/09 | 61 | 19 | Docetaxel-capecitabine | Breast only | Affymetrix U133 Plus 2.0 Array | 20012355 |
| GSE19697 | 10/30/09 | 24 | 24 | Epirubicin-docetaxel | Breast or lymph nodes | Affymetrix U133 Plus 2.0 Array | 19967557 |
| GSE16446 | 1/26/10 | 120 | 85 | Epirubicin | Breast or lymph nodes | Affymetrix U133 Plus 2.0 Array | 21422418 |
| GSE20194 | 2/4/10 | 278 | 277 | TFAC | Breast or lymph nodes | Affymetrix U133A Array | 21978456 |
| GSE22513 | 6/23/10 | 28 | 28 | Paclitaxel with radiation | Breast or lymph nodes | Affymetrix U133 Plus 2.0 Array | 20068102 |
| GSE20271 | 10/15/10 | 178 | 178 | FAC/TFAC | Breast or lymph nodes | Affymetrix U133A Array | 20829329 |
| GSE22093 | 12/31/10 | 103 | 97 | FEC/FAC | Breast or lymph nodes | Affymetrix U133A Array | 21191116 |
| GSE23988 | 2/7/11 | 61 | 61 | FEC-T | Breast or lymph nodes | Affymetrix U133A Array | 21191116 |
| GSE28796 | 4/22/11 | 24 | 12 | Docetaxel | Breast or lymph nodes | Affymetrix U133 Plus 2.0 Array | 21633166 |
| GSE25066 | 5/11/11 | 508 | 79 | Anthracycline-taxane | Breast or lymph nodes | Affymetrix U133A Array | 21558518 |
| GSE25066 | 5/11/11 | NA | 58 | Anthracycline-taxane | Breast or lymph nodes | Affymetrix U133A Array | 21558518 |
| GSE32646 | 3/20/12 | 11 5 | 11 5 | P-FEC | Breast or lymph nodes | Affymetrix U133 Plus 2.0 Array | 22320227 |
| Affymetrix Total | 1602 | 1033 | |||||
| Agilent Dataset | |||||||
|---|---|---|---|---|---|---|---|
| Dataset (NCBI GEO) | Date of GEO | Cases in dataset | Evaluable | Chemotherapy | Response Definition | Platform | Reference (PMID) |
| GSE8465 | 1/12/08 | 46 | 35 | GD-GC | Breast only | Agilent-012097 Human 1A Microarray (V2) G4110B | 18382427 |
| GSE21974 | 5/25/10 | 57 | 32 | EC-T | Breast or lymph nodes | Agilent-014850 Whole Human Genome Microarray G4112F | 21769435 |
| GSE22358 | 3/18/11 | 158 | 95 | Docetaxel-capecitabine | Breast only | Agilent 1X44K Custom Array | 21373875 |
| GSE21997 | 5/27/11 | 98 | 94 | Doxorubicin vs. docetaxel | Breast or lymph nodes | Agilent Custom Array | 21465170 |
| GSE22226 | 1/13/12 | 150 | 130 | AC-T | Breast or lymph nodes | Agilent-012391 Whole Human Genome Microarray G4112A | 22198468 |
| Agilent Total | 509 | 386 | |||||
Chemotherapy Abbreviations: FEC: 5-FU, epirubicin, cyclophosphamide; FEC-T: 5-FU, epirubicin, cyclophosphamide, paclitaxel; TFAC: paclitaxel, 5-FU, doxorubicin, cyclophosphamide; TFAC: paclitaxel, 5-FU, doxorubicin, cyclophosphamide; PFEC: paclitaxel, 5-FU, epirubicin, cyclophosphamide; EC-T: epirubicin/cyclophosphamide followed by docetaxel; AC-T: doxorubicin/cyclophosphamide followed by docetaxel; GD-GC: Gemcitabine/doxorubicin followed by gemcitabine/cisplatin.